Brief: All Endpoints Met in Hepion Pharmaceuticals’ Drug-Drug Interaction Study with CRV431
29/09/2021 14:30
Sept 29 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* ALL ENDPOINTS MET IN HEPION PHARMACEUTICALS' DRUG-DRUG
INTERACTION STUDY WITH CRV431
Source text for Eikon: ID:nGNXg7JJP
Further company coverage: HEPA.O
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement